GordonMD Global Investments LP 的 Form 4/A 修正申報
修正Pyxis Oncology, Inc.PYXS，2026/10/9 申報
- 申報編號
- 0000919574-26-006815
- 申報時間
- 2026/10/9 14:39 ET
- 交易日
- 2026/10/1
- 申報延遲
- 8 天
- 10b5-1 計畫
- 沒有勾選
- 原始申報日
- 2026/10/2
這份申報列了 1 筆衍生性交易。沿用原件裡沒有重述的 1 筆交易。交易後 8 天申報。
這份修正申報重述了 0000919574-26-006609（2026/10/2 申報）的一部分，沒有重述的交易仍然有效，列在下面。
申報人
一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| GordonMD Global Investments LPCIK 0002039349 | 持股 10% 以上大股東 |
| GordonMD Long Biased GP LLCCIK 0002103778 | 持股 10% 以上大股東 |
| GordonMD Long Biased Master Fund LPCIK 0002103789 | 持股 10% 以上大股東 |
| Gordon Craig DCIK 0002103811 | 持股 10% 以上大股東 |
非衍生性證券（表 I）
普通股等股票的取得與處分，每一列是申報上的一筆。
這份申報沒有這一類的交易。
衍生性證券（表 II）
選擇權、認股權證、限制型股票單位等。股數是標的股票的股數；單價與金額是衍生證券本身的價格，交易後持有是衍生證券的單位數。
| 交易日 | 證券 | 交易 | 標的股數 | 單價 | 金額 | 交易後持有 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2026/10/1 | Common Stock | P買進取得 | +7,172,000 | –F2 | – | 7,172,000 | 間接 |
沿用原件的交易
這份修正申報只重述了原件的一部分。原件其他的交易仍然有效，網站的交易表把它們算在這份修正申報底下。
來自 0000919574-26-006609（2026/10/2 申報）。
非衍生性證券（表 I）
| 交易日 | 證券 | 交易 | 股數 | 價格 | 金額 | 交易後持股 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2026/10/1 | Common Stock, par value $0.001 per share ("Common Stock") | P買進取得 | +5,517,000 | –F2 | – | 15,541,909 | 間接 |
原件的附註
這幾筆交易的價格在原件上引用的附註。
- F2
The combined public offering price for each share of common stock and accompanying Common Stock Purchase Warrant is $2.90.
表 I 有 1 筆交易的價格引用這則附註。
附註與備註
本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。
- F1
The securities to which this filing relates are held directly by GordonMD Long Biased Master Fund LP (the "Master Fund") to which GordonMD Global Investments LP (the "Investment Manager") serves as investment manager. Craig D. Gordon ("Mr. Gordon") is the managing member of GordonMD Long Biased GP LLC (the "GP"), the general partner of the Master Fund. Each of the Master Fund, the GP and Mr. Gordon disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any.
- F2
The combined public offering price for each share of common stock and accompanying Common Stock Purchase Warrant is $2.90.
表 II 有 1 筆交易的價格引用這則附註。
- F3
Exercise price of $3.5, subject to adjustments as set forth in the Common Stock Purchase Warrant.
- F4
The Common Stock Purchase Warrant will not be exercisable unless and until (i) the issuer's stockholders approve an amendment to the issuer's amended and restated certificate of incorporation to increase the number of authorized shares of Common Stock (the "Charter Amendment") and (ii) the Charter Amendment is filed with, and becomes effective under the laws of, the State of Delaware (the date on which the Charter Amendment becomes effective, the "Charter Amendment Effective Date").
- F5
The Common Stock Purchase Warrant will expire on the earlier of (i) the fifth anniversary of the Charter Amendment Effective Date and (ii) the 30th calendar day following the later of the Charter Amendment Effective Date and the date on which the issuer publicly discloses the results of the overall survival analysis for its Phase 1 monotherapy study of MICVO in second-line and later recurrent or metastatic head and neck squamous cell carcinoma.
備註
This Form 4/A is being filed to correct the number of Common Stock Purchase Warrant reported in the Form 4 filed by the Reporting Persons with the Securities and Exchange Commission on October 2, 2026.